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Abstract
Introduction: Acute trauma involving the anterior cruciate ligament is believed to be a major risk factor for the
development of post-traumatic osteoarthritis 10 to 20 years post-injury. In this study, to better understand the early
biological changes which occur after acute injury, we investigated synovial fluid and serum biomarkers.
Methods: We collected serum from 11 patients without pre-existing osteoarthritis from a pilot intervention trial (5
placebo and 6 drug treated) using an intra-articular interleukin-1 receptor antagonist (IL-1Ra) therapy, 9 of which
also supplied matched synovial fluid samples at presentation to the clinic after acute knee injury (mean 15.2 ± 7.2
days) and at the follow-up visit for reconstructive surgery (mean 47.6 ± 12.4 days). To exclude patients with pre-
existing osteoarthritis (OA), the study was limited to individuals younger than 40 years of age (mean 23 ± 3.5) with
no prior history of joint symptoms or trauma. We profiled a total of 21 biomarkers; 20 biomarkers in synovial fluid
and 13 in serum with 12 biomarkers measured in both fluids. Biomarkers analyzed in this study were found to be
independent of treatment (P > 0.05) as measured by Mann-Whitney and two-way ANOVA.
Results: We observed significant decreases in synovial fluid (sf) biomarker concentrations from baseline to follow-
up for sfC-Reactive protein (CRP) (P = 0.039), sflubricin (P = 0.008) and the proteoglycan biomarkers:
sfGlycosaminoglycan (GAG) (P = 0.019), and sfAlanine-Arginine-Glycine-Serine (ARGS) aggrecan (P = 0.004). In
contrast, we observed significant increases in the collagen biomarkers: sfC-terminal crosslinked telopeptide type II
collagen (CTxII) (P = 0.012), sfC1,2C (P = 0.039), sfC-terminal crosslinked telopeptide type I collagen (CTxI) (P = 0.004),
and sfN-terminal telopeptides of type I collagen (NTx) (P = 0.008). The concentrations of seven biomarkers were
significantly higher in synovial fluid than serum suggesting release from the signal knee: IL-1b (P < 0.0001), fetal
aggrecan FA846 (P = 0.0001), CTxI (P = 0.0002), NTx (P = 0.012), osteocalcin (P = 0.012), Cartilage oligomeric matrix
protein (COMP) (P = 0.0001) and matrix metalloproteinase (MMP)-3 (P = 0.0001). For these seven biomarkers we
found significant correlations between the serum and synovial fluid concentrations for only CTxI (P = 0.0002), NTx
(P < 0.0001), osteocalcin (P = 0.0002) and MMP-3 (P = 0.038).
Conclusions: These data strongly suggest that the biology after acute injury reflects that seen in cartilage explant
models stimulated with pro-inflammatory cytokines, which are characterized by an initial wave of proteoglycan loss
followed by subsequent collagen loss. As the rise of collagen biomarkers in synovial fluid occurs within the first
month after injury, and as collagen loss is thought to be irreversible, very early treatment with agents to either
reduce inflammation and/or reduce collagen loss may have the potential to reduce the onset of future post-
traumatic osteoarthritis.
Trial registration: The samples used in this study were derived from a clinical trial NCT00332254 registered with
ClinicalTrial.gov.
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Acute trauma to the anterior cruciate ligament (ACL) or
meniscus has recently been demonstrated to be a major
risk factor for the development of osteoarthritis (OA)
with a 50% chance of a patient developing symptomatic
OA 10 to 20 years post-injury repair [1]. ACL injuries
represent a quarter of all knee injuries with an annual
incidence of at least 81 per 100,000 population which
equates to at least 246,000 ACL injuries and more than
175,000 reconstructions in the US annually among per-
sons aged 10 to 64 years old [2]. Knee injury is a leading
cause of OA in young people, with young women having
a three- to five-fold higher risk of an ACL injury than
young men [1,3]. A prospective study of young adults
revealed a 14% cumulative incidence of self-reported
knee OA by the age of 65 years for those who had any
knee injury during their adolescence or young adulthood
c o m p a r e dw i t ha6 %i n c i d e n c ef o rt h o s ew i t h o u tah i s -
tory of knee joint injury [4]. Post-traumatic OA is
believed to account for up to 5.6 million per year or
12% of the total US cases of symptomatic OA with an
estimated cost in 2006 of $3.06 billion per year or 0.15%
of total US direct health care costs [5,6]. It is increas-
ingly believed that the development of later OA in the
injured joints is initiated by both bone and cartilage
damage caused during the initial traumatic and inflam-
matory event coupled with possible long term changes
t oj o i n tl o a d i n g .A f t e ri n j u r y ,i ti sp r o p o s e dt h a ta b n o r -
mal joint motion and loading lead to a biological
response dominated by catabolic activity [1,7]. However,
unlike primary OA, post-traumatic secondary OA is
initiated by intra-articular pathogenic processes with a
known date of onset, namely the date of joint injury.
This makes it much more amenable to early interven-
tion than primary OA whose onset is not clearly defin-
able at this time.
Following acute trauma, an initial flare of cytokines
has been reported which mirrors that seen in wound
healing and includes tumor necrosis factor (TNF)a,
interleukin (IL)-1b,I L - 6 ,I L - 8 ,I L - 1r e c e p t o ra n t a g o n i s t
(IL-1Ra) and IL-10 [8]. Cartilage damage has been
demonstrated by the release of proteoglycan and col-
lagen fragments after ACL rupture [9,10]; release is
m a x i m a li nt h ef i r s tf e ww e e k sb u tc a np e r s i s ta ta
significantly elevated concentration in synovial fluid for
decades following injury [10-15]. Other matrix mole-
cules such as matrix metalloproteinase (MMP)-3, tissue
inhibitor of metalloproteinase (TIMP)-1 and cartilage
oligomeric matrix protein (COMP) have also been
demonstrated to have persistently elevated concentra-
tions in synovial fluid after ACL injury [15,16] The
increased matrix turnover may not be limited to merely
the affected knee as there is evidence to suggest that the
concentrations of aggrecan, COMP and MMP-3 are also
elevated in the uninjured contralateral knee of ACL rup-
ture patients [17], possibly as a consequence of altered
loading. A canine ACL rupture model of OA also
demonstrates increased synthesis and turnover of pro-
teoglycan in early arthritis [18,19]. Thus, biomarker pro-
files could potentially indicate risk for progression to
OA based on the identities, quantities, and temporal
patterns of expression of specific joint tissue compo-
nents. In this study we investigated a wide range of
synovial fluid and serum biochemical biomarkers, at two
time points, to better understand the changes and
damage which occur to both the bone and cartilage
early in the course of severe knee trauma. Many biomar-
kers are not specific for the joint and there is a possibi-
lity that the concentrations of a particular biomarker,
when measured in the serum, could be affected by
release from alternative sites due to increased systemic
inflammation following acutei n j u r y .T h e r e f o r e ,i nt h i s
study we also investigated the relationship between the
serum and synovial fluid concentrations of individual
biomarkers to determine whether measurements made
in the serum reflect the concentrations observed within
the signal knee.
Materials and methods
Sample collection
All samples were collected with informed consent and
this research was performed with the approval of the
Duke University Investigational Review Board and was
carried out in compliance with the Helsinki Declaration.
Synovial fluid and matched serum samples were col-
lected at baseline (within four weeks of injury) and at
follow-up at the time of arthroscopic repair surgery.
Synovial fluid was centrifuged (8°C, 3,500 g, five min-
utes), and the supernatant aliquoted and frozen at -80°C
within two hours of collection. Serum was also aliquoted
and frozen at -80°C until analysis.
Patient characteristics
Samples for this study were derived from a randomized
double-blinded placebo-controlled pilot trial of a single
injection of the short-acting intra-articular IL-1Ra ther-
apy, anakinra, administered at the time of presentation
to the clinic [20]. The samples used in this study were
derived from a clinical trial, NCT00332254 registered
with ClinicalTrial.gov. The trial consisted of 11 patients,
5 saline injected placebo and 6 anakinra injected study
participants. We collected serum from 11 patients, 9 of
which also supplied matched synovial fluid samples (4
placebo and 5 drug), who presented to the Duke Sports
Medicine clinic with a history of recent (within the pre-
vious month) severe knee injury due to sports injury.
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mean age at enrollment of 23 ± 3.5 years and a 6/5
male/female split. The study was limited to individuals
younger than 40 years of age with no prior history of
joint symptoms or trauma to exclude patients with pre-
existing OA. Patients were enrolled as soon after initial
injury as possible with a mean baseline enrollment time
of 15.2 ± 7.2 days after injury and a mean follow-up
time of 47.6 ± 12.4 days after injury with samples
collected at time of surgery. The joint pathology was
defined by clinical knee magnetic resonance images
obtained prior to the baseline assessments, and included,
in addition to evidence of ACL tear in all patients, other
knee joint tissue damage including bone contusions,
medial collateral ligament tears, meniscal tears and
chondral defects. All biomarkers within this report were
found to be independent of treatment by both two-way
Analysis of Variance (ANOVA) and by Mann-Whitney
tests, so for the purposes of statistical analysis, we com-
bined the drug and control groups to improve statistical
power.
Biomarker analyses
We investigated a range of biomarkers summarized in
Table 1. The majority of biomarker measurements were
obtainable with commercially available reagents and
assays were performed as per the manufacturer’s
instructions (details in Table 1). The remaining biomar-
ker assays utilized methods that have been previously
described and summarized briefly below.
sGAG determination using alcian blue
A commercial sGAG kit was used as per the manufac-
turer’s instructions (Kamiya Biomedical Company, Seattle,
WA, USA). Briefly, 50 μl of each sample (either standard
or synovial fluid) was adjusted to 4 M guanidine-HCl by
addition of an equal volume of 8 M guanidine-HCl, mixed
and incubated at room temperature (RT) for 15 minutes.
A further 50 μl of a 0.3% volume/volume (v/v) H2SO4 and
0.75% v/v Trition X-100 solution was added, mixed and
incubated at RT for 15 minutes. After incubation, 750 μl
of alcian blue solution (0.03 M Guanidine-HCl, 0.1% v/v
H2SO4, 0.25% v/v triton X-100) was added, mixed
and incubated for 15 minutes at RT before centrifugation
at 12,000 g for a further 15 minutes. The supernatant
was discarded and 500 μlo fd i m e t h y ls u l f o x i d es o l u t i o n
(40% v/v DMSO, 0.05 M MgCl2) added and mixed for
15 minutes at RT before centrifugation at 12,000 g for
15 minutes. The supernatant was discarded and the
pellet redissolved in Gu-Prop solution (4 M Guanidine-
HCl, 33% v/v 1-propanol, 0.25% v/v triton X-100) for
15 minutes on a shaker. Samples were read at 595 nm and
the GAG level determined from a linear standard curve
(12.5 to 400 μg/ml).
Table 1 Summary and sources of the assays used in this study
Analyte Details Assay (Reference) Sample Supplier
IL-1b Inflammatory Cytokine ELISA [8] SF, Serum R&D Systems, Minneapolis, MN
hsCRP Inflammatory marker ELISA [43] SF, Serum United Biotech, Inc, Mountain View, CA
Sulphated GAG Total proteoglycan loss (mainly aggrecan) Chemical assay SF Kamiya Biomedical Company, Seattle, WA
ARGS-aggrecan Aggrecan cleavage assay ELISA [21] SF Pfizer In house
FA846 Fetal aggrecan matrix protein (CS846 epitope) ELISA SF, Serum IBEX, Montreal, Quebec, Canada
CS846 Aggrecan epitope Competitive ELISA [43] Serum IBEX, Montreal, Quebec, Canada
C2C Collagenase neoepitope of Collagen II ELISA [43] SF, Serum IBEX, Montreal, Quebec, Canada
CTxII Collagen II degradation marker ELISA [43] SF Nordic Bioscience, Herlev, Denmark
C1,2C Type I/II collagen degradation ELISA [43] SF, Serum Nordic Bioscience, Herlev, Denmark
CTxI Type I collagen degradation ELISA [44] SF, Serum Osteometer MediTech, Inc, Hawthorene, CA
NTX Bone formation marker ELISA [45] SF, Urine Osteomark, Princeton, NJ
CPII Collagen II synthesis marker ELISA [43] SF, Serum IBEX, Montreal, Quebec, Canada
Osteocalcin Bone synthesis marker ELISA [43] SF, Serum Quidel Corporation, San Diego, CA
b-Aspartate Age dependant protein modification Enzyme Assay [46] SF, Serum Promega, Madison, WI
D-Asx Age dependant protein modification HPLC [22] SF, Serum Kraus laboratory In house
D-Serine Age dependant protein modification HPLC [22] SF, Serum Kraus laboratory In house
sCD44 Cartilage marker ELISA [47] SF, Serum eBioscience, Inc, San Diego, CA
COMP Cartilage matrix protein ELISA [23] SF, Serum Kraus laboratory
Tenascin C Cartilage matrix protein ELISA [48] SF IBL International GmbH, Toronto, ON, Canada
Lubricin Cartilage matrix protein ELISA SF Pfizer In house
MMP-3 Proteolytic enzyme ELISA [49] SF, Serum R&D Systems, Inc., Minneapolis, Mn
COMP, cartilage oligomeric matrix protein; CRP, C-reactive protein; GAG, glycosaminoglycan.
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Synovial fluid samples were adjusted to contain 50 mM
Tris Acetate, 0.1 M NaCl and 5 mM CaCl2,p H7 . 3 ,a n d
1× protease inhibitor cocktail I (Calbiochem/EMD
Chemicals, Gibbstown, NJ, USA). Samples were deglyco-
sylated by treating with 0.2 U/ml chondroitinase ABC,
0.2 U/ml keratanase, and 0.02 U/ml keratanase II (Seika-
gaku America, Falmouth, MA, USA) at 37°C for two to
three hours. Sample dilutions were then applied to
microtiter plate wells coated with anti-human aggrecan
mAb AHP0022 (Invitrogen, Carlsbad, CA, USA) and
incubated for two hours at RT. After washing, horse rad-
ish peroxidase (HRP)-labeled anti-ARGS monoclonal
antibody (mAb) BC-3 (Abcam, Cambridge, UK) was
added to the wells, followed by incubation for 1.5 hours
at RT, washing, and detection with 3,3’, 5,5"-tetramethyl-
benzidine (TMB) One Component HRP substrate (BioFX
Laboratories, Owings Mills, MD, USA). The concentra-
tion of ARGS-aggrecan for each sample was determined
based on a standard curve generated using ADAMTS4-
digested human aggrecan as previously described [21].
FA-846 fetal aggrecan sandwich ELISA
FA-846 aggrecan was measured as per the manufac-
turer’s (IBEX, Montreal, QC, Canada) instructions.
Briefly, 50 μl of assay buffer and either 50 μl of diluted
sample or standards were added to each well of a pre-
coated plate and incubated at RT for 1.5 hours with
shaking (600 to 700 rpm). The plate was washed six
times using the supplied wash buffer before addition of
100 μl of biotinylated FA-846 antibody (50 μlo fs t o c k
diluted in the supplied buffer II) and incubated with
shaking for 30 minutes at RT. Excess antibody was
removed with a further six washes with the supplied
wash buffer before the addition of 100 μlo f5p g / m l
streptavidin-HRP diluted in buffer II and incubation for
30 minutes at RT with shaking. Excess streptavidin-HRP
was removed with six washes before the addition of 100
μl/well of TMB reagent. Once developed, the TMB reac-
tion was stopped using 100 μl/well of stop solution and
read at 450 nm.
Quantification of racemized amino acids
Racemized Asx (Aspartate and Aspargine) and Serine
concentrations in synovial fluid were quantified using a
previously described high performance liquid chromato-
graphy (HPLC) approach developed and validated in our
laboratory [22]. Briefly, purified proteins were acid
hydrolyzed in 6 M HCl at 105°C for 8 h. The resulting
free D- and L-amino acids were derivatized to fluores-
cent compounds by addition of o-phthaldialdehyde and
N-tert-butyloxycarbonyl-L-cysteine. The subsequent
derivatives were separated by reversed-phase HPLC
using a C18 column and mobile phases of 0.2 M acetic
acid adjusted to a pH of 6.0 and an acetonitrile gradient.
The resulting peaks were quantified fluorometrically
(ex340 nm, em440 nm) by comparison to commercially
available pure D- and L-amino acids (Sigma-Aldrich,
St. Louis, MO, USA).
COMP ELISA
S e r u ma n ds y n o v i a lf l u i dC O M Pw e r eq u a n t i f i e db y
ELISA using the mAb 16F12 for capture and biotiny-
lated mAb 17C10 for detection as previously described
[23] with the following minor modifications. Plates were
blocked with 3% BSA/PBS/0.02% sodium azide for two
hours. Synovial fluid was diluted 1:400 and 1:800. Strep-
tavidin-alkaline phosphatase conjugate (ExtrAvadin,
Sigma, St. Louis, MO, USA) was diluted 30,000 × in
0.01% BSA/PBS/0.02% sodium azide and the phospha-
tase substrate (4-nitrophenyl phosphate disodium salt
hexahydrate, Sigma) was used as the detection agent.
Plates were read at wavelength 405 nm after 20 minutes
of incubation.
Lubricin ELISA
Synovial fluid samples were deglycosylated as described
for the ARGS-aggrecan ELISA before sample dilutions
were applied to microtiter plate wells coated with an
anti-lubricin mAb (Clone 5; Pfizer, Cambridge, MA,
USA) and incubated for one hour at RT. After washing,
a second anti-lubricin mAb (HRP-lableled Clone 26;
Pfizer) was added to the wells, followed by incubation
for one hour at RT, washing, and detection with TMB
One Component HRP substrate (BioFX Laboratories,
Owings Mills, MD, USA). The concentration of lubricin
for each sample was determined based on a standard
curve generated using a recombinant human lubricin
protein construct, LUB1 [24].
Statistical methods
Statistical analyses were performed using GraphPad
Prism version 4.02 (GraphPad Software, Inc, La Jolla,
C A ,U S A ) .D u et ot h es m a l ls a m p l es i z eu s e di nt h i s
study it was not realistic to assume a Gaussian distribu-
tion and so all statistical tests used were non-parametric:
for all correlations Spearman Rank correlation was used;
for paired data Wilcoxon Signed Rank test was used.
Samples for this study were derived from a pilot trial of
a single injection, intra-articular anti-IL-1 therapy [20]
and as described above, the drug and control groups
were combined for purposes of statistical analysis.
Results
Biomarker concentrations in the setting of acute knee
injury
To gain an understanding of the effect of joint injury on
joint tissue turnover and pathology, we investigated 20
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acute knee injury and after a period of recovery but
prior to surgery.
Initially we compared the baseline and follow-up data
for each biomarker to determine whether there were
any significant changes in biomarker concentrations
between the two time points (Table 2). In synovial fluid
(sf), we observed a significant decrease between the two
collection time points for the inflammatory marker
sfCRP (P = 0.039), the cartilage superficial zone protein
sflubricin (P = 0.008) and the biomarkers of proteogly-
can: sfGAG (P = 0.019) and the aggrecanase cleaved
aggrecan marker sfARGS aggrecan (P =0 . 0 0 4 ) .W e
observed decreasing trends for the remaining inflamma-
tion and joint tissue biomarkers, sfIL-1b (P = 0.124),
fetal aggrecan sfFA846 (P =0 . 0 7 4 )a n dsfCOMP (P =
0.055). In contrast, we observed significant increases
between the two time points for several of the synovial
fluid biomarkers of collagen turnover: C-terminal cross-
linked telopeptide type II collagen (sfCTxII) (P =0 . 0 1 2 ) ,
sfC1,2C (P = 0.039), C-terminal crosslinked telopeptide
type I collagen (sfCTxI) (p = 0.004) and N-terminal telo-
peptides of type I collagen (sfNTx) (P =0 . 0 0 8 ) .W h i l e
we observed small increases in the collagen degradation
marker sfC2C, the collagen synthesis marker sfCPII, and
the bone synthesis marker sfOsteocalcin, these were not
significant and may reflect the limitation of our small
sample size. Finally we observed an increasing trend for
the biomarker of protein age, D-Serine (P = 0.055).
In the serum (s) we observed fewer significant
changes, with only sOsteocalcin (P = 0.032) demonstrat-
ing a significant decrease between the two time points,
while both CTxI (P = 0.083) and NTx (P = 0.054)
showed increasing trends with time, which were consis-
tent with the observations in synovial fluid. We also
used the complementary approach of Spearman Rank
Correlation to analyze time from injury and synovial
fluid biomarker concentration. Interestingly, we
observed significant decreases with time for sfCRP (P =
0.041, rs = -0.473), sfGAG (P = 0.027, rs = -0.506),
sfARGS aggrecan (P = 0.003, rs = -0.638), sfb-Aspartate
(P =0 . 0 2 5 ,r s = -0.525) and sflubricin (P =0 . 0 2 7 ,r s =
-0.506), while the collagen markers sfCTxII (P = 0.002,
rs = 0.659) and sfC1,2C (P = 0.005, rs = 0.613) demon-
strated significant increases with time.
Comparison of biomarkers in matched serum and
synovial fluid
To investigate whether the biomarker values measured
in serum behaved as surrogates for the concentrations
found within the signal knee after acute injury, we com-
pared biomarker concentrations in synovial fluid and
serum from the matched samples collected from the
same patients. Due to assay sensitivity and specificity,
we were able to measure 12 of the 20 synovial fluid bio-
markers in matched serum and synovial fluid samples
(Table 2). We hypothesized that biomarkers produced
in the injured signal knee would have significantly
higher concentrations in the synovial fluid than in the
circulating serum. When we compared the concentra-
tions of the 12 biomarkers measured in both fluids,
seven demonstrated significantly higher concentrations
in the synovial fluid than serum: IL-1b (P < 0.0001),
FA846 (P = 0.0001), CTxI (P = 0.0002), NTx (P =
0.012), Osteocalcin (P = 0.012), COMP (P = 0.0001) and
MMP-3 (P = 0.0001). The biggest differences between
synovial fluid and serum were observed for MMP-3 and
COMP with fold differences of 738.8 and 21.2 respec-
tively. Smaller fold differences were observed for FA846
(5.9×), IL-1b (4.3×), CTxI (1.6×), NTx (1.2×) and osteo-
calcin (1.2×). The inflammatory marker CRP, produced
in the liver, showed significantly higher concentrations
(P = 0.012) in the serum than in synovial fluid (3.5×).
It is of note that CRP is not an OA specific marker, it is
an acute phase protein and upregulated in many different
conditions, which limits its specificity. We also observed
significantly higher concentrations of C1,2C (P = 0.005)
in the serum suggesting a systemic source or rapid clear-
ance from the joint for this biomarker (1.8×).
To further investigate the utility of the serum biomar-
kers to reflect signal knee synovial fluid concentrations,
we performed Spearman Rank correlations between the
matched synovial fluid and serum samples. Of the seven
biomarkers with significantly higher concentrations in
synovial fluid than serum, the concentrations of four
biomarkers were found to correlate between the two
fluids; CTxI (P =0 . 0 0 0 2 ) ,N T x( P < 0.0001), osteocalcin
(P = 0.0002) and MMP-3 (P = 0.038) (Table 2). These
data strongly suggest a signal knee source of these bio-
markers and the ability of a serum concentration to
reflect early signal knee events following acute injury.
Of note, the acute phase reactant protein, CRP, demon-
strated the reverse pattern; CRP concentrations in
s e r u me x c e e d e dt h o s ei ns y n o v i a lf l u i da n dt h e r ew a sa
significant correlation (P = 0.002) between the serum
and synovial fluid concentration compatible with passive
diffusion of CRP into the synovial fluid, suggesting a
systemic response to acute injury rather than a signal
knee specific response. In the acute injury phase, the
duration and/or level of elevation of CRP in the serum
may be a useful indicator of extent and severity of tissue
injury but this would require correlation with arthro-
scopic or MRI assessments of joint inflammation and
injury.
Discussion
It is important to understand the amount and type of
joint damage after acute injury to identify novel
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Synovial Fluid Levels Serum Levels Serum vs Synovial Fluid
Biomarker Baseline
Mean
±SD
Follow
Up Mean
±SD
P-value Baseline
Mean
±SD
Follow
Up Mean
±SD
P-value Mean Ratio (synovial
fluid/serum levels) ± SD,
P-value
Correlation (between serum
and synovial fluid levels), P-
value
Inflammation markers
IL-1b (pg/
ml)
1.02 ±
0.66
0.61 ±
0.22
P = 0.124 0.17 ±
0.06
0.24 ±
0.12
P = 0.102 ↑4.3 ± 2.1, p < 0.0001 rs = 0.358, P = 0.123
CRP (μg/
ml)
1.67 ±
1.28
0.68 ±
0.64
P = 0.039 3.18 ±
2.93
1.78 ±
2.10
P = 0.102 ↓3.5 ± 4.2, p = 0.012 rs = 0.658, P = 0.002
Proteoglycan markers
GAG (μg/
ml)
330.7 ±
203.2
170.2 ±
45.9
P = 0.008 ——— — —
ARGS
aggrecan
(μg/ml)
230.7 ±
236.7
63.2 ±
54.0
P = 0.004 ——— — —
FA846
(ng/ml)
1134.0 ±
158.1
886.5 ±
295.8
P = 0.074 31.2 ±
35.1
32.4 ±
43.8
P = 0.520 ↑59.1 ± 6.3, p = 0.0001 rs = -0.179, P = 0.464
CS846
(ng/ml)*
——— 72.3 ±
139.2
58.1 ±
131.6
P = 0.413 ——
Collagen markers
C2C (ng/
ml)
184.1 ±
37.6
208.9 ±
56.3
P = 0.301 226.5 ±
34.8
216.3 ±
49.2
P = 0.700 ↓1.2 ± 0.5, p = 0.232 rs = -0.463, P = 0.046
CTxII (μg/
L)
0.59 ±
0.58
1.09 ±
0.63
P = 0.012 ——— — —
C1,2C
(μg/ml)
0.28 ±
0.10
0.37 ±
0.08
P = 0.039 0.53 ±
0.18
0.51 ±
0.19
P = 0.638 ↓1.8 ± 1.2, p = 0.005 rs = 0.209, P = 0.391
CTxI (ng/
ml)
0.75 ±
0.39
1.23 ±
0.67
P = 0.004 0.52 ±
0.32
0.66 ±
0.31
P = 0.083 ↑1.6 ± 0.5, p = 0.0002 rs = 0.819, P < 0.0001
NTx (nM
BCE)
15.58 ±
4.37
19.64 ±
7.78
P = 0.008 18.67 ±
6.92
21.6 ± 4.2 P = 0.054 ↑1.2 ± 0.2, p = 0.012 rs = 0.828, P < 0.0001
CPII (ng/
ml)
308.1 ±
257.4
318.3 ±
185.1
P = 0.820 365.2 ±
181.5
288.2
±106.8
P = 0.102 ↑1.3 ± 0.9, p = 0.976 rs = -0.102, P = 0.679
Osteocalcin
(ng/ml)
15.43 ±
4.99
17.08 ±
6.16
P = 0.301 19.91 ±
8.54
16.3 ± 5.6 P = 0.032 ↑1.2 ± 0.3, p = 0.012 rs = 0.747, P = 0.0002
Post-translational markers of protein age
b-
Aspartate
(μM)
0.94 ±
0.32
0.76 ±
0.37
P = 0.129 ——— — —
D-Asx (D/
D+L)
0.018 ±
0.001
0.019 ±
0.002
P = 0.423 ——— — —
D-Serine
(D/D+L)
0.002 ±
0.001
0.003 ±
0.001
P = 0.055 ——— — —
Other Biomarkers
sCD44
(ng/ml)*
128.1 ±
49.0
105.0 ±
28.2
P = 0.250 115.9 ±
26.9
110.7 ±
39.0
P = 0.820 ↑1.1 ± 0.4, p = 0.922 rs = 0.301, P = 0.226
COMP
(μg/ml)
140.9 ±
65.4
99.1 ±
32.3
P = 0.055 8.6 ± 4.1 8.0 ± 4.4 P = 0.278 ↑21.2 ± 15.3, P = 0.0001 rs = -0.326, P = 0.173
Tenascin
C (ng/ml)
813.2 ±
428.6
908 ± 599 P = 0.570 ——— — —
Lubricin
(nM equ)
390.4 ±
159.6
215.9 ±
59.0
P = 0.008 ——— — —
MMP-3
(ng/ml)
29.02 ±
20.84
30.89 ±
26.56
P =
0.910
0.05 ±
0.02
0.04 ±
0.02
P =
0.148
↑738.8 ± 602.5, P = 0.0001 rs = 0.479, P = 0.038
Results represent mean ± SD data for n = 9 patients for synovial fluid values and for serum n =1 1o rn = 9 for * marked biomarkers due to sample depletion.
Non-parametric paired analyses by Wilcoxon Signed Rank test were performed to evaluate for significant differences between baseline and follow up time points
and between serum and synovial fluid values. Non parametric Spearman Rank correlations (rs) were performed to determine correlations between synovial fluid
and serum and the ratios reported are mean ratios ± SD.
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Page 6 of 9therapeutic strategies that could be employed to better
treat the symptoms and reduce the future risk of post-
traumatic OA development. In this study we investi-
gated the changes in biomarker concentrations at the
time of sports-related acute knee injury and after a
short period of recovery prior to surgery in 11 young
patients with a mean age of 23 years. The patients were
all part of a small randomized placebo-controlled pilot
study of IL-Ra to determine the feasibility and establish
the methodology for future clinical trials in acute joint
injury. The initial samples were obtained prior to IL-1Ra
injection and the second set of samples was obtained a
mean four weeks later. No statistical difference was
observed between the treatment and placebo arms for
any of the biomarkers presented in this paper although
we acknowledge that a sample of this size may have lim-
ited power to detect such differences. However, we
believe it is reasonable to expect that these effects on
the biomarker levels would be minimal because a single
dose of IL-1Ra has a very short in vivo half-life, esti-
mated at four to six hours after bolus subcutaneous
injection [25]. We investigated a total of 21 different
biomarkers representing a wide range of joint relevant
molecules in both synovial fluid and serum to better
understand the changes which occur after acute injury
a n dt oi d e n t i f yb i o m a r k e r sw h i c hm i g h tb em o s tu s e f u l
for following the effectiveness of future disease modify-
ing protocols.
The investigation of several different classes of bio-
markers after acute injury demonstrated that the proteo-
glycan biomarkers (sfGAG, sfARGS aggrecan and
sfFA846) decreased with time from injury which mir-
rored the inflammation biomarker sfCRP and sflubricin.
A decreasing trend was also observed for sfCOMP, while
interestingly sfMMP-3 did not change over time. In con-
trast, all the collagen and bone biomarkers increased
with time from injury. Taken together, these results
demonstrate that the cartilage within the injured joint
responds to the initial acute injury with a wave of pro-
teoglycan and non-collagenous protein loss. However, as
the concentrations of proteoglycans and small cartilage
molecules declined, there was apparent onset of collagen
damage with a rise in synovial fluid collagen biomarkers.
These in vivo findings after acute injury are analogous
to the temporal patterns of matrix epitope release in
vitro from cartilage explants stimulated with proinflam-
matory cytokines in which there is an initial loss of pro-
teoglycan followed by collagen loss [26]. It has long
been known from animal studies [27,28] that the loss of
proteoglycan is reversible while once the collagen is lost,
the cartilage is irreparably damaged [29]. Since these
data show significant cartilage collagen epitope loss in
vivo within even the first montha f t e ri n j u r y ,i tw o u l d
appear that critical and possibly irreversible damage is
sustained within weeks of severe knee injury with an
ACL tear. These data suggest the possible need for very
early intervention to prevent post-traumatic-osteoarthri-
tis. More detailed studies are required to better charac-
terize these early changes and to link them to the future
risk of post-traumatic OA known from previous studies
to be 50% by 10 to 15 years following ACL injury [1,3].
The most likely cause of this observed early cartilage
and joint damage after acute injury is through the effect
of pro-inflammatory cytokines released into the synovial
fluid. This observed inflammatory driven damage
matches that observed in pro-inflammatory cytokine-
induced cartilage degeneration in explant models [26]
and the catabolic processes observed in rheumatoid
arthritis and preclinical animal models of OA. These
observations suggest that some of the already existing
small molecules that have demonstrated chondroprotec-
tive effects in vitro, in animal models and in humans
with rheumatoid arthritis may constitute new treatment
strategies to prevent the irreversible cartilage damage in
t h ef o r mo fc o l l a g e nl o s sa f t e ra c u t ei n j u r ya n dt h e r e b y
offer the hope of preventing future onset of injury
related OA. These include: the biologic anti-cytokine
therapies directed towards IL-1a, TNFa or IL-6 that are
successful rheumatoid arthritis therapies [30]; p38 mito-
gen activated protein kinases (MAPK) pathway inhibi-
tors, protective in a rat model of OA [31,32] and in
explant culture [33]; statins that inhibit cartilage break-
down by reducing protein prenylation [34,35]; and sulfa-
zalazine that can inhibit collagenase production by
inhibiting the NFkB pathway in cartilage explant models
[36]. Direct inhibition of catabolic enzymes may also be
a viable short term target for cartilage and joint protec-
tion after acute injury. Inhibition of proteoglycan loss
has been shown to be effective at preventing OA in ani-
mals [37-39] while inhibition of the collagen degrading
collagenase enzymes can protect cartilage from irreversi-
ble collagen loss [40]. Any of these potential therapies
could be administered early after acute injury for a short
period of time to prevent the initial and potentially irre-
parable cartilage and joint damage which occurs after
acute injury.
In this study we also compared the concentrations of
different biomarkers in the synovial fluid and the serum
to determine how the serum concentrations reflect the
changes in the signal knee. These data are important for
future clinical trials as measuring biomarkers in the
serum is easier than obtaining serial synovial fluid sam-
ples. Only MMP-3 and the bone biomarkers, CTxI, NTx
and osteocalcin demonstrated a significant correlation
between serum and synovial fluid concentrations
suggesting that these serum biomarkers may accurately
reflect the activity in the signal knee. The lack of correla-
tion between the serum and synovial fluid concentrations
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Page 7 of 9for many of the standard biomarkers may be due to their
rapid clearance from the joint or systemic circulation, or
significant confounding of serum concentrations by other
sources of biomarker epitopes. While there has been
much research using these biomarkers (see comprehen-
sive recent reviews by van Spil et al. [41] and Kraus et al.
[42]), more research is required to better profile both the
currently available biomarkers and to develop more spe-
cific biomarkers which are less sensitive to systemic
contributions.
Conclusions
The results presented in this manuscript demonstrate
that there is significant and measurable cartilage and
bone damage after acute knee injury. We also noted
that the release of biomarkers from cartilage matches
the profile observed from in vitro cartilage explants
models treated with pro-inflammatory cytokines. This
similarity between the damage which occurs in acute
injury and the cartilage explant models suggests that
much of the chondroprotective research performed in
cartilage explant systems could be directly translated to
the treatment of acute injury to reduce or even prevent
early cartilage damage, thereby potentially reducing the
risk of later early onset OA.
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